Conventional vs. newer antipsychotics in elderly patients

American Journal of Geriatric Psychiatry

Volumn 7, Issue 1, 1999, Pages 70-76

  Jeste, Dilip V ^a   Rockwell, Enid ^b   Harris, M Jackuelyn ^b   Lohr, James B ^b   Lacro, Jonathan ^b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; THIORIDAZINE;

AGITATION; AGRANULOCYTOSIS; ANTICHOLINERGIC EFFECT; ARTICLE; CATARACT; CLINICAL TRIAL; COGNITION; DEMENTIA; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LEUKOPENIA; NEGATIVE SYNDROME; ORTHOSTATIC HYPOTENSION; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TARDIVE DYSKINESIA; VERTIGO;

EID: 0032933361     PISSN: 10647481     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019442-199902000-00010     Document Type: Article

References (33)

1. Kane JM, Woerner M, Lieberman J: Tardive dyskinesia: prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988; 8:52S-56S
2. Jeste DV, Caligiuri MP, Paulsen JS, et al: Risk of tardive dyskinesia in older patients: a prospective longitudinal study of 266 patients. Arch Gen Psychiatry 1995; 52:756-765
3. Jeste DV, Rockwell E, Harris MJ, et al: Incidence of tardive dyskinesia in early stages of treatment with typical neuroleptics in older patients. AmJ Psychiatry (in press)
4. Schooler N, Kane JM: Research diagnoses for tardive dyskinesia. Arch Gen Psychiatry 1982; 39:486-487
5. National Institute of Mental Health: Abnormal Involuntary Movement Scale (AIMS). Early Clinical Drug Evaluation Unit Intercom 1975; 4:3-6
6. Harris MJ, Heaton RK, Schalz A, et al: Neuroleptic dose reduction in older psychotic patients. Schizophr Res 1997; 27:241-248
7. Gilbert PL, Harris MJ, McAdams LA, et al: Neuroleptic withdrawal in schizophrenic patients. Arch Gen Psychiatry 1995; 52:173-188
8. Jeste DV, Lacro JP, Gilbert PL, et al: Treatment of late-life schizophrenia with neuroleptics. Schizophr Bull 1993; 19:817-830
9. Kane JM, Honigfeld G, Singer J, et al: Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
10. Marder SR, Meibach RC: Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151:825-835
11. Meltzer HY, Fibiger HC: Olanzapine: a new atypical antipsychotic drug. Neuropsychopharmacology 1996; 14:83-85
12. Small JG, Hirsch SR, Arvanitis LA, et al: Quetiapine in patients with schizophrenia. Arch Gen Psychiatry 1997; 54:549-557
13. Kane JM, Woerner MG, Pollack S, et al: Does clozapine cause tardive dyskinesia?. J Clin Psychiatry 1993; 54:327-330
14. Saltz BL, Woerner MG, Kane JM, et al: Prospective study of tardive dyskinesia incidence in the elderly. JAMA 1991; 266:2402-2406
15. Salzman C, Vacarro B, Lieff J, et al: Clozapine in older patients with psychosis and behavioral disruption. Am J Geriatr Psychiatry 1995; 3:26-33
16. Chengappa KNR, Baker RW, Kreinbrock SB, et al: Clozapine use In female geriatric patients with psychoses. J Geriatr Psychiatry Neurol 1995; 8:12-15
17. Kahn N, Freeman A, Juncos JL, et al: Clozapine is beneficial for psychosis in Parkinson's disease. Neurology 1991; 41:1699-1700
18. Factor SA, Brown D: Clozapine prevents recurrence of psychosis in Parkinson's disease. Mov Disord 1992; 7:125-131
19. Jeste DV, Eastham JH, Lacro JP, et al: Management of late-life psychosis. J Clin Psychiatry 1996; 57(suppl 3):39-45
20. Jeste DV, Eastham JH, Gierz M, et al: Use of risperidone in the elderly, in The Art of Rational Risperidone Therapy. Edited by Ayd FJ. Baltimore, MD, AYD Medical Communications, 1997, pp 147-167
21. Folstein MF, Folstein SE, McHugh PR: Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
22. Jeste DV, Lohr JB, Eastham JH, et al: Adverse neurobiological effects of long-term use of neuroleptics: human and animal studies. J Psychiatr Res (in press)
23. Berman I, Merson A, Rachov-Pavlov J, et al: Risperidone in elderly schizophrenic patients: an open-label trial. Am J Geriatr Psychiatry 1996; 4:173-179
24. Green MF; Marshall BD, Wirshing WC, et al: Does risperidone improve verbal working memory in treatment-resistant schizophrenia? AmJ Psychiatry 1997; 154:799-804
25. Green MF: What are the functional consequences of neurocognitive deficits in schizophrenia? AmJ Psychiatry 1996; 153:321-330
26. Klapow JC, Evans J, Patterson TL, et al: Direct assessment of functional status in older patients with schizophrenia. AmJ Psychiatry 1997; 154:1022-1024
27. Hoff AL, Faustman WO, Wieneke M, et al: The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology 1996; 15:361-369
28. Tollefson GD, Beasley CM, Tran PV, et al: Olanzapine vs. haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. AmJ Psychiatry 1997; 154:457-465
29. Tollefson GD, Beasley CM, Tamura RN, et al: Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997; 154:1248-1254
30. Wolters EC, Jansen ENH, Tuynman-Qua HG, et al: Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996; 47:1085-1087
31. Arvanitis LA, Miller BG, the Seroquel Trial 13 Study Group: Multiple fixed doses of "seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol Psychiatry 1997; 42:233-246
32. Meltzer HY, Cola P, Way L, et al: Cost effectiveness of clozapine in neuroleptic-resistant schizophrenia. Am J Psychiatry 1993; 150:1630-1638
33. Hargreaves WA, Shumway M: Pharmacoeconomics of antipsychotic drug therapy. J Clin Psychiatry 1996; 57:66-76